Princeton, New Jersey, USA, November 18, 2026
Bristol Myers Squibb (BMS) has presented the first clinical findings from two Phase 3 studies evaluating KarXT (xanomeline and trospium chloride) for the treatment of psychosis associated with Alzheimer’s disease. The preliminary findings from the ADEPT clinical development programme showed improvements in hallucinations, delusions and overall disease severity during the open-label treatment periods of the ADEPT-1 and ADEPT-3 studies. The data were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Massachusetts, on November 18, 2026. KarXT was generally well tolerated in both studies, with no new safety signals identified. The findings represent the first clinical data disclosure from the Phase 3 ADEPT programme and provide an initial assessment of short-term symptom changes and longer-term safety. However, the double-blind treatment periods remain ongoing, and the reported open-label findings are preliminary descriptive analyses rather than confirmatory evidence of efficacy.
ADEPT-1 Study Shows Improvements in Psychosis Symptoms
The ADEPT-1 Phase 3 study is evaluating KarXT in adults experiencing psychosis associated with Alzheimer’s disease. Its design includes a 12-week open-label treatment period followed by a 26-week double-blind, randomized withdrawal phase. At the time of the reported analysis, 320 participants had enrolled, of whom 273 (85.3%) completed the initial 12-week open-label period. Participants receiving KarXT demonstrated improvements in clinician-assessed hallucinations and delusions, measured using the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) scale. The mean score decreased by 12.0 points from a baseline of 14.4 among 266 participants assessed. The Clinical Global Impression-Severity (CGI-S) score, which measures overall disease severity, also improved, with a mean reduction of 1.9 points from a baseline of 4.5 among 267 participants. Treatment-emergent adverse events were reported in 56.6% of participants, while serious adverse events occurred in 5.0%. Adverse events leading to treatment discontinuation were reported in 4.4%. These observations provide an initial indication of symptom changes during treatment, although the open-label design does not allow the improvements to be attributed conclusively to the investigational treatment.
ADEPT-3 Provides 52-Week Safety and Tolerability Data
The ADEPT-3 study is a global, 52-week open-label extension designed to evaluate the longer-term safety and tolerability of KarXT in patients who completed the double-blind portions of ADEPT-1, ADEPT-2 or ADEPT-4. Among 401 participants enrolled at the time of analysis, 273 participants (68.1%) completed the 52-week treatment period. The findings showed that KarXT was generally well tolerated, with a relatively low rate of treatment discontinuation. Treatment-emergent adverse events occurred in 65.1% of participants, serious adverse events in 7.7%, and adverse events leading to discontinuation in 4.7%. Improvements in clinician-observed symptoms were also reported. The mean NPI-C H+D score decreased by 5.1 points from an open-label baseline of 8.9, based on 270 participants. The CGI-S score showed a mean reduction of 0.8 points from a baseline of 3.4, based on 277 participants. These results offer preliminary information about treatment exposure over one year. However, because ADEPT-3 is an open-label extension, the observations should be interpreted as descriptive findings rather than evidence from a controlled comparison.
KarXT Mechanism and Next Steps in Phase 3 Development
KarXT combines xanomeline and trospium chloride in an oral formulation designed to modulate central cholinergic muscarinic receptor pathways. Xanomeline is a dual M1- and M4-preferring muscarinic receptor agonist intended to influence neurological pathways involved in cognition and behaviour. Trospium chloride is included to reduce peripheral cholinergic side effects. KarXT is already FDA-approved in the United States under the brand name Cobenfy for schizophrenia in adults, but its use for psychosis associated with Alzheimer’s disease remains investigational. Psychosis can affect an estimated 30% to 50% of people with Alzheimer’s disease during the course of the condition. Hallucinations and delusions can increase distress for patients and caregivers and complicate disease management. Currently, there are no FDA-approved medicines specifically indicated for psychosis associated with Alzheimer’s disease, creating a significant unmet medical need.
The broader ADEPT programme includes ADEPT-2 and ADEPT-4, which are evaluating the acute efficacy of KarXT, alongside ADEPT-5, which is investigating twice-daily dosing. Importantly, the double-blind treatment-period results from the ADEPT studies remain blinded. These controlled data will be essential to determine whether the preliminary improvements translate into demonstrated treatment benefits. Bristol Myers Squibb plans to continue evaluating KarXT’s efficacy, safety and tolerability as the Phase 3 programme progresses.
Source: Bristol Myers Squibb press release



